Navigation Links
New study spotlights National Institutes of Health grant outcomes for clinical research
Date:7/25/2008

Although the need to translate basic science discoveries into the clinical arena is widely acknowledged, a new study by researchers at the Medical College of Wisconsin, in Milwaukee, and National Institutes of Health (NIH) identified reasons why clinical science grant applications receive less positive peer reviews than basic science grant applications to the NIH. The findings were published in the July issue of The American Journal of Medicine.

In collaboration with Michael R. Martin, Ph.D., and Teresa Lindqusit, MS, at NIH's Center for Scientific Review CSR), Dr. Theodore Kotchen, associate dean for clinical research and professor of medicine at the Medical College, studied 92,922 grant applications submitted to NIH between October 2000 and May 2004. Of that number, 67.5 percent were considered basic science applications and 32.5 percent were considered clinical applications. Dr. Kotchen is special advisor on clinical research to the NIH's CSR.

They found that investigators conducting clinical research were less likely to submit a continuing, competitive renewal grant application than investigators conducting basic research (20.0% vs. 28.3%). However, renewal applications generally receive more favorable reviews than new applications. The study concluded that approximately one-half of the observed differences in peer review outcomes for clinical versus basic research applications can be attributed to the lower rate of resubmission by clinical applicants.

Another reason for differences in review outcomes was related to applicants failing to adequately address human subject concerns in their applications. Human subject concerns, which the NIH defines as any potential or actual unacceptable risk or inadequate protection against risks to human subjects, were identified in 15% of clinical grant applications.

"Applications cited for having human subject concerns do not necessarily mean that the science is less meritorious," says Dr. Kotchen.

"Human subject concerns raised at the time of review may reflect inadequate explanation by the investigator in the protection of human subjects section of the application. Further instructions clarifying how to complete the human subject section of grant applications may be necessary.

"The message to applicants is that failure to provide complete information about plans for protecting human subjects may result in a less favorable priority and could adversely affect the likelihood of funding."

According to Kotchen, "There are continuing national concerns about the robustness of the clinical research enterprise. This includes a shortage of clinical investigators, the attrition of experienced clinical investigators, lack of adequate infrastructure at academic medical centers, and the financial burden faced by promising young scientists."

He points out that, "The clinical research enterprise would benefit from an informed understanding of the factors contributing to the attrition of experienced clinical investigators."

Clinical research grants were defined as any grants that include involvement of human subjects. This definition includes research on mechanisms of disease, therapeutic interventions, clinical trials, development of technologies, epidemiological and behavioral studies outcomes, and health services research.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-456-4744
Medical College of Wisconsin
Source:Eurekalert

Related biology news :

1. Antimicrobial sutures reduce infections in brain shunt surgery, study finds
2. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
3. Landscape study may offer solutions for fire managers
4. Study: Typhoons bury tons of carbon in the oceans
5. Study shows parasites outweigh predators
6. Rutgers biologist to study worms in Amazon, glaciers
7. Study suggests past climate changes may have promoted the formation of new species in the Amazon
8. Sugar study is sweetener for stem cell science
9. MSU researcher uses grant to study little-known but largely useful microbes
10. Scripps study sets high economic value on threatened Mexican mangroves
11. Study reveals air pollution is causing widespread and serious impacts to ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , ... January 17, 2017 ... ... surgeons at the 2016 annual meeting of the North American Spine Society ... for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, ... recently announced a collaboration with the Heidelberg University Hospital and the German Cancer ... preparation, following the company’s successful launch of its CATS (Capture and Amplification ...
(Date:1/16/2017)... 16, 2017   Valentin A. Pavlov, PhD , ... president and CEO of The Feinstein Institute for ... of how the nervous system regulates the immune system, ... bioelectronic medicine devices to treat disease and injury. ... . The paper examines various studies which ...
(Date:1/14/2017)... ARLINGTON, Va. , Jan. 13, 2017  The ... following statement in response to FDA final guidance ... FDA for its continued leadership in emphasizing the importance ... members are keenly aware of the benefits biosimilars will ... costs.   Yet the portion of the ...
Breaking Biology Technology: